Chloroethyl Benzo[d]Imidazole Ester Preparation With Stoichiometric Control

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The existing method for preparing 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl esters using oxalyl chloride and dimethylformamide results in undesirable yellow coloration and impurities, which are difficult to remove, and lacks precise control over the reaction stoichiometry.

Innovation Solution

A method using chloromethylenedimethyliminium chloride in a stoichiometric or superstoichiometric ratios to convert 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl esters, allowing for better control over the reaction and minimizing impurities, with the option to form a novel formylated derivative.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If oxalyl chloride is used in superstoichiometric excess (≥2.6 mol, particularly ≥3.0 mol) to ensure complete conversion, then the yield of 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester is improved, but the reaction produces undesirable yellow coloration and difficult-to-remove impurities

Engineering Contradiction:
Improveyield of 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl esterVSAvoidyellow coloration and impurities
Core Design Contradiction:
ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the molar ratio parameter from superstoichiometric (≥2.6:1) to substantially stoichiometric (1.95:1 to 2.05:1), which eliminates the yellow coloration and impurities while maintaining high conversion efficiency. This precise parameter control resolves the contradiction between complete conversion and product purity.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses dimethylcarbamoyl chloride as a substitute reagent that replicates the chlorination function of oxalyl chloride but without producing the harmful yellow byproducts. This alternative chemical pathway achieves the same transformation goal while avoiding the harmful effects.

Inventive Principle:
Principle #26Copying

2Productivity

If oxalyl chloride reaction with dimethylformamide is used to convert hydroxyethyl groups to chloroethyl groups, then the desired product is obtained in good yield, but the reaction becomes difficult to control regarding completeness and interfering moisture

Engineering Contradiction:
Improveyield of chlorinated productVSAvoidcontrol over reaction completeness and moisture interference
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent removes dimethylformamide from the reaction system entirely, using only dimethylcarbamoyl chloride as the reagent. This eliminates the problematic intermediate formation and moisture sensitivity issues associated with the oxalyl chloride-dimethylformamide system, while maintaining effective chlorination capability.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs dimethylcarbamoyl chloride as a single-use reagent that performs the chlorination function and is then discarded, avoiding the need for complex intermediate handling and purification steps required by the oxalyl chloride-dimethylformamide system. This simplifies the process and improves reliability.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Object-generated harmful factors

If activated carbon treatment is applied to remove yellow coloration, then some impurities are reduced, but the yellow coloration remains difficult to remove completely

Engineering Contradiction:
Improveyellow coloration intensityVSAvoiddifficulty of impurity removal
Core Design Contradiction:
Object-generated harmful factorsVSEase of manufacture

Solution Approach 1:

The patent performs preliminary action by precisely controlling the stoichiometry of the chlorination reaction from the outset, preventing the formation of yellow byproducts before they occur. This proactive approach eliminates the need for subsequent activated carbon treatment entirely, making the purification process trivial.

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method achieves high yields of 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl esters with reduced impurities and enables the production of a novel formylated derivative with potential anti-tumor activity, offering improved occupational safety and reaction control.

Implementation Method 1

The reactants used are 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl esters, the hydroxyethyl groups of which can be converted into chloroethyl groups by reaction with oxalyl chloride

Methodology Applied
Scientific EffectChemical reaction: Chemical Bonding

Implementation Method 2

The in-situ reaction of oxalyl chloride with dimethylformamide used here is difficult to control with regard to the completeness of the reaction

Methodology Applied
Scientific EffectChemical reaction: Chemical Bonding

Implementation Method 3

Ester hydrolysis can cause 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl esters to be converted to 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid

Methodology Applied
Scientific EffectHydrolysis: Hydrolysis

Data Source

PatentUS20250295636A1Method for preparing 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1h-benzo[d]imidazol-2-yl]butyric acid alkyl esters and formylated derivatives
Publication Date: 2025.09.25 HERAEUS PRECIOUS METALS GMBH & CO KG

AI summary

A method for preparing a 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1 H-benzo[d]imidazol-2-yl]butyric acid alkyl ester, wherein 1 mol of 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester is reacted with 2.0 to 2.2 mol of chloromethylenedimethyliminium chloride or with >2.2 to 5 mol of chloromethylenedimethyliminium chloride to prepare a by-product in the form of a 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1 H-benzo[d]imidazol-2-yl]butyric acid alkyl ester. The alkyl ester can be hydrolyzed to form 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H benzo[d]imidazol-2-yl]butyric acid that is usable in the field of medicine.